Docket No.: C1271.70022US02

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Larry R. Krepski et al.

Serial No.: 10/595,959
Confirmation No.: 9672
Filed: May 22, 2006

For: SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS

Examiner: R. J. Desai

Art Unit: 1625

## Certificate of Electronic Filing Under 37 CFR 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: July 15, 2009 Signature: /Heather A. McLennand/ (Heather A. McLennand)

## RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam:

In response to the restriction requirement set forth in the Office Action mailed May 15, 2009, Applicant hereby elects Group I (claims 1-3, 5, 7-8, 11-12, 15, 17-23, 25-26, 29, 36-42, 49-52, and 54), drawn to compounds and pharmaceutical compositions wherein the compound is a tricyclic, *i.e.*, R<sub>A</sub> and R<sub>B</sub> form a 6-membered carbocyclic ring, R<sub>2</sub> is an alkyl or an alkyl substituted by an alkoxy, X is a alkylene chain, Z is C=O, and R<sub>1-1</sub> is an alkyl, a phenyl, a -N(CH<sub>3</sub>)OCH<sub>3</sub>, or a cycloalkyl, for prosecution in the present application. Furthermore, Applicant elects the compound of Example 24 (S-34240) on page 107 as the species for search purposes. The claims encompassing the elected species include claims 1, 2, 5, 7-8, 11, 15, 17-23, 25-26, 29, 36-42, 49-52, and 54.

The Examiner states that Group I comprises claims 21-3, 5, 7-8, 11-12, 15, 17-23, 25-26, 29, 36-42, 49-52, and 54. Applicant points out that independent claim 3 and dependent claim 10 do not fall within the scope of Group I as described. Consequently, Group I encompasses claims 1, 2, 5, 7-8, 11, 15, 17-23, 25-26, 29, 36-42, 49-52 and 54.

Application No.: 10/595,959 2 Docket No.: C1271,70022US02

Having made the election, Applicant expressly reserves the right to pursue the subject matter of the non-elected claims in one or more future applications claiming priority to the present application.

Applicant is filing concurrently a Petition for a one-month extension of time and authorization to pay the required extension fee. If there is a fee occasioned by this response that is not covered, please charge any deficiency to Deposit Account No. 23/2825, under Docket No. C1271.70022US02, from which the undersigned is authorized to draw.

Dated: July 15, 2009 Respectfully submitted,

By /C. Hunter Baker/ C. Hunter Baker, M.D., Ph.D. Registration No.: 46,533 WOLF, GREENFIELD & SACKS, P.C. Federal Reserve Plaza 600 Atlantic Avenue Boston, Massachusetts 02210-2206 617.646,8000